Welcome to our dedicated page for Know Labs SEC filings (Ticker: KNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive associated with the historical ticker KNW provides a detailed record of Know Labs, Inc.’s regulatory disclosures as it developed radio frequency spectroscopy and RFDS technology and later transformed into USBC, Inc. Investors can review Forms 10‑K and 10‑Q for information on the company’s RFDS‑based diagnostic platform, its plans for a non‑invasive glucose monitor that will require FDA clearance, and the role of Know Labs Technology Licensing (KTL) in licensing RFDS and the e‑RFDS© digital watermark to external partners.
More recent Form 8‑K filings document key corporate events. An 8‑K dated February 18, 2025 describes a 1‑for‑40 reverse stock split and the company’s move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings related to bid price requirements. Subsequent 8‑Ks filed in July and August 2025 outline the Securities Purchase Agreement with Goldeneye 1995 LLC, the bridge financing arrangement, shareholder approvals to increase authorized common stock and amend the 2021 Equity Incentive Plan, and the closing of a private placement in which the buyer acquired approximately 81% of the company’s common stock.
These filings also explain how preferred stock series were converted or redeemed, how legacy debt instruments were repaid or satisfied with cash and common stock, and how the company adopted indemnification agreements for directors and officers. An 8‑K filed on August 15, 2025 reports the completion of the name change to USBC, Inc. and ticker change to USBC on the NYSE American, as well as the change of principal executive offices to Reno, Nevada.
On Stock Titan, users can access these historical KNW filings as they were submitted to EDGAR and use AI‑powered summaries to interpret complex sections. This includes quickly understanding material contracts, capital structure changes, reverse stock split mechanics, change‑of‑control terms, and ongoing risk disclosures related to the company’s RFDS technology, licensing activities, and later digital asset‑focused strategies.
Know Labs (KNW) has issued a preliminary proxy statement ahead of a virtual special meeting scheduled for July 24, 2025. Shareholders of record on June 20, 2025 will vote on four proposals:
- Authorized Share Increase (Proposal 1) – amendment of the Articles of Incorporation to expand authorized common stock from 7.5 million to 750 million shares.
- Private Placement (Proposal 2) – approval to issue shares exceeding 19.99 % of outstanding stock and the resulting change of control linked to a June 6, 2025 Securities Purchase Agreement with Goldeneye 1995 LLC.
- Equity Incentive Plan (Proposal 3) – increase the 2021 Plan share reserve by 35 million shares.
- Adjournment (Proposal 4) – authority to adjourn the meeting if necessary to secure sufficient votes.
The Board unanimously recommends voting “FOR” all proposals, citing enhanced capital flexibility and alignment of incentives. Materials will be mailed on or about July 3, 2025, and voting can be completed online, by telephone, or by mail.
If adopted, the proposals would provide significant funding capacity but also introduce substantial dilution risk—a 100-fold increase in authorized shares and a transaction that may transfer control to Goldeneye 1995 LLC.
Know Labs, Inc. (KNW) Schedule 13G – Insider ownership disclosure
Ronald P. Erickson, the company’s founder and long-time executive, together with his controlled entity J3E2A2Z LP (collectively the “Reporting Persons”), has filed a Schedule 13G indicating beneficial ownership of 1,492,092 common shares, equal to 19.99 % of Know Labs’ 7,497,948 outstanding shares as of 12 Jun 2025. The filing date that triggered the report is 06 Jun 2025; signatures are dated 20 Jun 2025.
Capital-structure details
- Direct holdings: 137,202 common shares
- Preferred: 16,916 Series H Preferred shares (issued 2 Jun 2025 via conversion of $1.184 million of convertible promissory notes) are convertible into 3,534,525 common shares.
- Warrants: 97,367 common-share purchase warrants outstanding.
However, the Series H Preferred and warrants are subject to a 19.99 % beneficial-ownership blocker; therefore only 1,492,092 shares are currently deemed beneficially owned. The filing certifies that the securities were not acquired to change or influence control of the issuer.
Key implications for investors
- The debt-to-equity conversion removes $1.18 million of obligations, strengthening the balance sheet.
- Insider alignment is high, with Erickson at the 20 % reporting threshold.
- Full conversion of Series H Preferred and warrants could add up to ~3.6 million new shares, a material dilution risk once the blocker is waived or exceeded.